肿瘤诊治新视角:血液炎症指标的临床应用与研究进展

New Perspectives in the Diagnosis and Treatment of Tumor: Clinical Applications and Research Progress of Blood Inflammatory Indicators

在肿瘤的诊断与治疗领域,血液炎症指标作为评价患者免疫与炎症状态的重要工具,已逐渐显现其临床价值。中性粒细胞与淋巴细胞比值(Neutrophil to Lymphocyte Ratio, NLR)、血小板与淋巴细胞比值(Platelet to Lymphocyte Ratio, PLR)以及全身免疫炎症指数(Systemic Immune-Inflammation Index, SII)等指标可用于评估患者的免疫和炎症状况。近年来,学者们发现血液炎症指标与恶性肿瘤的发病、进展和预后密切相关。本文从诊断、预后评估、治疗疗效监测和免疫炎症反应评估等方面,对血液炎症指标在恶性肿瘤中的应用及研究进展进行综述,旨在为肿瘤临床诊治提供新的视角和实践依据。

In the field of tumor diagnosis and treatment, blood inflammatory indicators have become an im-portant tool for evaluating the immune and inflammatory status of patients, and their clinical value is gradually being recognized. Indicators such as the Neutrophil to Lymphocyte Ratio (NLR), Platelet to Lymphocyte Ratio (PLR), and the Systemic Immune-Inflammation Index (SII) can be used to as-sess the immune and inflammatory status of patients. In recent years, researchers have found that blood inflammatory indicators are closely related to the incidence, progression, and prognosis of malignant tumors. This article reviews the application and research progress of blood inflammatory indicators in malignant tumors from the aspects of diagnosis, prognostic evaluation, monitoring therapeutic efficacy, and assessing immune-inflammatory responses, with the aim of providing new perspectives and practical evidence for the clinical diagnosis and treatment of cancer.